Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.66 |
| ▸ | ESR1 | P03372 | 4/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245170 | 0.85 | ESR2 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL1487483 | 0.85 | ESR2 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL30475350 | 0.85 | ESR2 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL2958816 | 0.85 | ESR2 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL30233728 | 0.85 | ESR2 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL27975607 | 0.83 | ESR2 (0.76) | ESR2ESR1PTPN1CHRNA7 | |
| SCHEMBL29366409 | 0.83 | ESR2 (0.76) | ESR2ESR1PTPN1CHRNA7 | |
| SCHEMBL3693283 | 0.82 | ESR1 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL3693175 | 0.82 | ESR1 (0.67) | ESR2ESR1PTPN1 | |
| SCHEMBL7044126 | 0.81 | ESR2 (0.78) | ESR2ESR1PTPN1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187602-A4 | INJECTABLE SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND PROCESSES FOR PREPARING THE SAME | PEPTRON INC (KR) | 2004-09-15 | — | — | EP | claimed |
| US-20030026844-A1 | Injectable sustained release pharmaceutical composition and processes for preparing the same | PEPTRON, INC. (KR) | 2003-02-06 | — | — | US | claimed |
| EP-1187602-A1 | INJECTABLE SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND PROCESSES FOR PREPARING THE SAME | Peptron Inc. (KR) | 2002-03-20 | — | — | EP | claimed |
| WO-2001078687-A1 | INJECTABLE SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND PROCESSES FOR PREPARING THE SAME | PEPTRON INC. (KR) | 2001-10-25 | — | — | WO | claimed |
| US-5514670-A | HYDROPHOBIC CORES | PHARMOS CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| WO-1995005078-A1 | SUBMICRON EMULSIONS FOR DELIVERY OF PEPTIDES | PHARMOS CORPORATION (US) | 1995-02-23 | — | — | WO | claimed |
| WO-1991008220-A1 | A METHOD FOR THE STEPWISE, CONTROLLED SYNTHESIS OF CHEMICAL SPECIES, PARTICULARLY PEPTIDES, COUPLED PRODUCTS OBTAINED BY THE METHOD AND THE USE OF THESE COUPLED PRODUCTS, E.G. AS VACCINES | HOUEN GUNNAR (DK) | 1991-06-13 | — | — | WO | claimed |
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | MIDWESTERN UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4573371-A2 | DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY INJURY | The Johns Hopkins University (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240358798-A1 | TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES | SHEVY DRORA (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4364811-A2 | ALTERATIONS IN ENDOTHELIN RECEPTORS FOLLOWING HEMORRHAGE AND RESUSCITATION BY CENTHAQUIN | Midwestern University (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024040225-A9 | DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-0217822-A1 | HUMAN METALLOTHIONEIN-II PROMOTER IN MAMMALIAN EXPRESSION SYSTEM. | BIOTECH RES PARTNERS (US) | 1987-04-15 | — | — | EP | disclosed |
| US-4652549-A | POLYPEPTIDE | MERCK & CO., INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4618600-A | AURICULIN OR ANALOGS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4618600-A | AURICULIN OR ANALOGS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1986-10-21 | — | — | US | disclosed |
| WO-1986004920-A1 | HUMAN METALLOTHIONEIN-II PROMOTER IN MAMMALIAN EXPRESSION SYSTEM | BIOTECHNOLOGY RESEARCH PARTNERS, LIMITED (US) | 1986-08-28 | — | — | WO | disclosed |
| EP-0189084-A2 | Use of a peptide having cardiac anti-hypertrophic activity | MERCK & CO. INC. (US) | 1986-07-30 | — | — | EP | disclosed |
| EP-0182984-A2 | Use of fully synthetic alpha-human atrial natriuretic peptide (alpha-hANap) | PHARMA BISSENDORF PEPTIDE GMBH (DE) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | EDNRB, ADRA2B, ADRB2 | ESR2 101/4885ESR1 998/4885PTPN1 3404/4885 |
| US-20030026844-A1 | Injectable sustained release pharmaceutical composition and processes for preparing the same | FIBP, PGF, SSTR5 | ESR2 3819/4885ESR1 2608/4885PTPN1 1132/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | ESR2 544/4885ESR1 2651/4885PTPN1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.